629-635 (6 ) 0 390 -. 2 () *. oxidized LDL :. 2. 4 44 - : 259/59) 8-Iso-PGF2a.(P>... 54/00±0/36 ( 45 40) 85 : 0/05) (229/3. (P=0/03) (r=0/32) HbA C 8-Iso PGF2a.(P> HbA C (P=0/00) (r=0/4) 0/05). 8-Iso PGF2a LDL,HDL,TG, 8-Iso-PGF2a 8-Iso PGF2a :.. 2. 2 : - () : Abnoos.mokhtari@gmail.com : 66930040-9
2 () : 630 PG-Like F2isoprostane ( ) ( LDL ). - -2 MAP Kinase -3. -4-5 -6 [98] -7 2 invivo 2. () 44-2 4 (). 389 (group-matching) Consecutive BMI.. 90.. 2..[-3] (MDA)Malondialdehyde. LDL.. Advanced Glycation End Product.[4-6]. LDL oxidative susceptibility F2 isoprostanes F2 isoprostanes.[7] gold standard. Biomarker of oxidative stress study (BOSS) ISOPS approach.[74]
63 (6 ) 0 390 -.. 6 SPSS Code Sheet. Independent Sample T-test Pearson-. Regression Correlation.. 0/05 9 23 2) 85 54/00±0/36 ( 2 4 44. ( ) TG HBA C.. LDL. CHOLESTROL (r=0/03) LDL (r=0/0) (r=0/32) BMI (r=0/09) 8-Iso PGF2a (r=0/03) (r=0/07) HDL HbA C (r=0/0) TG (r=0/05) (r=0/4)...(2 ) (P=0/03) HbA C (P=0/00) (P=0/0 ß=0/58).(P=0/69) HbA C.(P=0/0) ( 0 CC ). -70. affinity binding assay %6/4 %4/4. (LDL).. BIOSOURCE COMPANY-IRMA. ASSAY 5/8 (NORMAL=2-25 MIU/ml) MIU/ml 8-IsoPGF2a Inter-assay DESIGN. 5/7assay.... ACEI ARB. mean Intra- 8-iso- amplitude glucose excursion (MAGE). PGF2α : IV III : BMI>35 GFR <60 E
2 () : 632-52± 55±9/6 26/8±3/2 27/4±3/8 (Kg/m2) BMI 85/9±8/ 87/2±67/2 * (mg/dl) 20±22/3 2/7±2/4 (mµ/ml) 35±62/8 85/±02/8 * (mg/dl) TG 83/±32/5 25/8±36/9 * (mg/dl) 92±7 3±9 * (mg/dl) LDL 43±4 43±6 (mg/dl) HDL 0/9±0/ 0/8±0/2 (mg/dl) Cr 380±46 439±8 (Pg/m) *.(P<0/05),HBA C, TG LDL 4 44 T-test : - : -2 r 0/09 0/03 0/03 0/4 0/ 0/07 0/07 0/ 0/32 (Kg/m2) BMI () * (mg/dl) (mg/dl) TG (mg/dl) (mg/dl) LDL (mg/dl) HDL *() HbA C.(P< 0/05),HBA C * 44 : Regression : - : 4. LDL ) OXIDATIVE SUSEPTIBILITY.( ( ) gold standard... HbA C.
633 (6 ) 0 390 -. 8-Iso PGF2a (r=0/07) (r=0/03) BMI (r=0/09) TG (0/05) LDL (r=0/03). (r=0/) HDL (r=0/0). (r=0/32) HbA C (r=0/4) (P=0/03) HbA C (P=0/00).(2 ) 8-Iso PGF2a HbA C Gopaul.,HOMA.[4] 8-Iso PGF2a HbA C Rytter [5]. 8-Iso PGF2a HbA C 8-Iso PGF2a. 8-Iso PGF2a 8-Iso PGF2a OXLDL 8-Iso PGF2a Zheng,Monnier MAGE (mean amplitude glucose excursion), (mean postprandial glucose excursion) MPPGE. Sampson.[27] 8-Iso PGF2a.[8] HbA C 8-Iso PGF2a Monnier [2] HbA C. Steady state. 40 ) (. invivo day to day MDA dose finding.[0-4] Marroe, 8-. Devaraj Rytter, Davi IsoPGF2α.[6527]. 4 44. 54±0/3. BMI ±9/3LDL) (83/±32/5 25/8 ±36/9) (85/9±8/ 87/2±67/2) HbA c (92/7±7/5 3/9 (35±62/8 85/±02/8) TG (P<0/05).. 8-Iso PGF2a (380 439).(P>0/05) 8-Iso Zheng Gopaul PGF2a.[47]
2 () : 634 ) ( NSAID MDA OXLDL. dose-finding... (RIA, ELIZA ).. 8-ISO-PGF2a. 8-ISO- 8-Iso PGF2a 8-Iso PGF2a. PGF2a HbA C.. Walter WC, Hughe VA, Clark RD. The relationship between Dietary habits, Blood glucose and insulin levels among people with type 2 diabetes. Rev Diabet Stud 2008; 2(40): 208-25. 2. Hyon K, Frontera WR, Andrews AW. Dietary habits and risk of type 2 diabetes. Arch Intern Med 2009; 6(5): 997-003. 3. Miller DL, FellJ, Patla AF. Diet and exercise habits of patients with diabetes. Journal of the American College of Nutrition 2007; 2(5): 394-396. 4. Mezzetti A, Cipollone F. Oxidative stress and cardiovascular complication in diabetes: isoprostane as new markers on an old paradigm. Cardiovascular Research 2000; 47:475-488. 5. Glugliano D. Oxidative stress and diabetes vascular complications. Diabetes Care 996; 9: 257-67. 6. Pasaoglu H, Sancak B, Bukan N. Lipid peroxidation and resistance to oxidation in patients with type II diabetes mellitus. Tohoku J Exp Med Jul 2004; 203(3):2-8. 7. Devaraj S, Hirany S. Divergence between LDL Oxidative susceptibitity and urinary F2- Isoprostanes as measure of Oxidative stress in type2 diabetes. Clinial Chemistry 200; 47: 974-979. 8. Steinberg D, Parthasarathy S, Carew TE, Khoo JC, Witztum JL. Beyond cholesterol. Modifications of low-density lipoprotein thatincrease its atherogenicity. N Engl J Med 989; 320(4):95-24. 9. Pratico D. F2 isoprostanes: Sensitive and specific non invasive indices of lipid peroxidation invivo. Atherosclero sclerosis 999; 47:-0. 0. Montuschi P, Barners P. Isoprostanes: markers and medication of oxidative stress. The FASEB J 2004; 8:79-800.. Hsiu Chuon Y. Detection of f2-isoprostanes and F4-neuroprostanes in clinical studies. J Biomed lab Sci 200; 9:-0. 2. Marrow J. Quantification of isoprostanes as indices of oxidant Stress and the risk of athero sclerosis in human. Arterio Scler Throm Vasc Biol 2005; 25:279-286. 3. Senturk UK, Gunduz F, Kuru U, Kipmem D, Yalcin O, Bor-Kucukatai M, et al. Exerciseinduced oxidative stress affect erythrocytes in sedentary rats but not in exercised- trained rat. J ApplPhysiol 200; 9:992-2004 4. Gopaul NK, Manraj MD, Hebe A, Lee K, Johnston A, Carrier M, et al. Oxidative stress could precede endothelial dysfunction and insulin resistance in Indian Mauritanians with impaired glucose metabolism. Diabetologia 200; 44:706-72. 5. Rytter E, Vessby B, Asgard R, Johansson C, Sjodin A, Abrahamsson L, et al. Glycaemic status in relation to oxidative stress and inflammation in well controlled type 2 diabetes
635 (6 ) 0 390 -. subjects. British Journal of Nutrition 2009; 0: 423 426. 6. Davi G. In vivo formation of 8-iso prostaglandin F2a and platelet activation in diabetes mellitus. Circulation 999; 99:224-229 7. Zheng F, Lu W, Jia C, Li H, Wang Z, Jia W. Relationships between glucose excursion and the activation of oxidative stress in patients with newly diagnosed type 2 diabetes or impaired glucose regulation. Endocr 200; 37: 20 208. 8. Sampson M, Gopaul N, Davis I, Hughes D, Carrier M. Plasm F2 isoprostanes. Diabetes Care 2002; 25: 537-54.